- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Preclinical Model to Guide Immunotherapeutic Development
Champions Oncology will be presenting data on it's preclinical model at the ongoing EORTC-NCI-AACR Symposium in Barcelona. The model proposes to help develop individualized treatments for patients.
Nov. 18-21
Barcelona, Spain
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the delivery of two presentations at the 26th EORTC-NCI-AACR Symposium, held in , discussing the creation of an innovative TumorGraft model (ImmunoGraft) specific to immune-modulating therapeutics and benefits of Champions' TumorGrafts® in guiding clinical development strategy.
Keren Paz
"There continues to be a need for improved models that enable researchers to better understand the clinical potential of therapeutics early in their development, ideally in the preclinical setting," said , Ph.D., chief scientific officer of Champions Oncology. "The findings presented at EORTC-NCI-AACR continue to demonstrate the advantages of our TumorGraft platform and our ability to create personalized mouse models for the exciting new class of immuno-oncology therapeutics. We look forward to presenting future case studies with our ImmunoGrafts at additional conferences in the year ahead."
Read the complete press release: http://prn.to/1F3F4M8
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
